To address unmet medical needs, Sorrento Therapeutics, Inc. (OTCMKTS: SRNE)—a clinical and commercial-stage biopharmaceutical company based in San Diego, California—uses its proprietary G-MAB™ antibody library in conjunction with targeted delivery modalities to develop innovative therapies for cancer, infectious diseases, and pain management. The company was founded in 2006.
Company Overview
Delivering clinically meaningful medicines through a wide portfolio is at the heart of Sorrento’s purpose. This includes:
- Cancer Therapeutics: With the use of proprietary platforms including CAR-T, DAR-T™, ADCs, and Seprehvec™ oncolytic viruses, among others
- Pain Management Solutions: Researching and developing alternatives to opioids for pain management, such as resiniferatoxin (RTX) and SEMDEXATM.
- Infectious Disease Treatments: Promising new vaccinations and antiviral treatments, like Abivertinib and diagnostic test solutions like COVISTIXTM and COVITRACKTM. leadiq.com
Sorrento Therapeutics, Inc. (OTCMKTS: SRNE) – Company Overview
| Category | Details |
|---|---|
| Company Name | Sorrento Therapeutics, Inc. |
| Stock Symbol | OTCMKTS: SRNE |
| Headquarters | San Diego, California |
| Founded | 2006 |
| Key Focus Areas | Cancer, Infectious Diseases, Pain Management |
| Proprietary Platforms | G-MAB™, CAR-T, DAR-T™, ADCs, Seprehvec™ |
| Revenue (2022) | $62.84 million (18.78% increase) |
| Net Loss (2022) | $572.84 million |
| Stock Performance | 40% spike over two weeks ending March 3, 2025 |
| Recent Corporate Action | Filed for Chapter 11 bankruptcy in February 2023 |
Financial Performance
Compared to the previous year, Sorrento’s sales in 2022 were $62.84 million, an increase of 18.78%. Nevertheless, because to the considerable expenses usually made in biopharmaceutical R&D, the company also generated losses of $572.84 million during that time.
Stock Performance
The OTC Markets are a platform where Sorrento’s shares can be traded using the symbol SRNE. A substantial 40% spike was noted over a two-week period ending March 3, 2025, indicating high volatility in the stock. Nevertheless, it is crucial to mention that the company has also had significant drops in value over the last year, which reflects the dangers connected with investing in biopharmaceuticals. investing.com
Recent Developments
U.S. Bankruptcy Court for the Southern District of Texas received Sorrento Therapeutics’ Chapter 11 reorganization petition in February 2023. This strategic decision was made with the intention of reorganizing the company’s debts and coming out on top when it came to creating treatments that could save lives.
Conclusion
With a strong pipeline focusing on important areas such as pain management, infectious illnesses, and cancer treatment, Sorrento Therapeutics, Inc. is leading the way in biopharmaceutical innovation. The company’s dedication to tackling unmet medical needs offers the chance for major advancements in healthcare, despite the risks posed by financial difficulties and market volatility.
FAQs
What is the primary focus of Sorrento Therapeutics?
Cancer, infectious illnesses, and pain management are the primary areas of focus for Sorrento Therapeutics’ next-generation therapy development efforts.
Where is Sorrento Therapeutics headquartered?
The company is headquartered in San Diego, California.
What are some of Sorrento’s proprietary platforms?
Sorrento makes use of oncolytic viruses including SeprehvecTM, as well as CAR-T and DAR-TTM platforms, ADCs, and others.
What was Sorrento’s revenue in 2022?
In 2022, Sorrento recorded $62.84 million in revenue.
What significant corporate action did Sorrento undertake in 2023?
Sorrento started the process of reorganizing its debts in February 2023 by filing for Chapter 11 bankruptcy.
Investors should refer to official company filings and reliable financial news sources for more precise information.
Call to Action
By signing up for our newsletter, you can keep up with the newest news in the biopharmaceutical business. Find out what’s happening in the industry and with new treatments by getting up-to-date information on firms like Sorrento Therapeutics, Inc.
